HOME >> MEDICINE >> NEWS
Analysis of tamoxifen studies reveals slight increase of stroke risk

ST. PAUL, Minn. A recent analysis of tamoxifen studies completed since 1980 revealed an increased risk of stroke in women who were randomized to tamoxifen versus placebo or other therapies. Details of the analysis and the researchers' conclusions are reported in the October 12 issue of Neurology, the scientific journal of the American Academy of Neurology.

More than 250,000 U.S. women are diagnosed with breast cancer each year. Breast cancer accounts for nearly one in three cancers diagnosed in the U.S. and is the second leading cause of death for women. Fortunately, 90 percent of breast cancers are now diagnosed at localized and regional stages, for which five-year survival rates are 97 percent and 79 percent, respectively. Tamoxifen, a medication in pill form that interferes with the activity of estrogen, has been used for more than 20 years to treat patients with advanced breast cancer. It is used as adjuvant, or additional, therapy following primary treatment for early stage breast cancer. In women at high risk of developing breast cancer, tamoxifen reduces the chance of developing the disease.

In addition to its effects on breast cancer, the benefits of tamoxifen include increased bone mineral density, reduced risk of hip fractures, and lower levels of cholesterol. While tamoxifen is known to increase the risk of blood clotting in women with cancer, its relationship to stroke risk has been unclear. Because tamoxifen increases the risk of thromboembolism (a blood clot that has traveled from its site of origin to another vessel), its use could be associated with a higher risk of ischemic stroke (arterial obstruction) as compared to hemorrhagic (bleeding) stroke.

Researchers from Duke University Medical Center sought to determine the overall risk of both ischemic stroke and all strokes associated with tamoxifen. They conducted a systematic review of all clinical trials of tamoxifen published since 1980 using MEDLINE.

Nine
'"/>

Contact: Marilee Reu
mreu@aan.com
651-695-2789
American Academy of Neurology
11-Oct-2004


Page: 1 2

Related medicine news :

1. Analysis finds drug improves odds of complete stroke recovery
2. Analysis of study looks at why quitters return to smoking
3. Analysis suggests women treated for breast cancer do better with axillary node dissection
4. Retrospective Statistical Analysis Corroborates Early Results Of Randomized Breast Cancer Trials
5. New U-M Analysis Of Brain At Work
6. Meta-Analysis Of The Efficacy Of Sildenafil (ViagraTM) In The Treatment Of Severe Erectile Dysfunction
7. Digital Speech Analysis Tests Sobriety
8. Common antidepressants lower effects of tamoxifen in many women
9. Study finds women hesitant to take tamoxifen as preventive measure
10. Decision to take tamoxifen difficult for many women
11. Chemotherapy, but not tamoxifen, associated with stroke risk after breast cancer treatment

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Analysis tamoxifen studies reveals slight increase stroke risk

(Date:3/6/2015)... The Public Health Accreditation Board ... status to seven more health departments. This week’s decisions ... people can now be assured that their health departments ... of their communities. , Public health departments play a ... people and communities. Across the nation, health departments provide ...
(Date:3/5/2015)... global digital PCR (dPCR) and qPCR market is expected to reach ... 2019. , The global digital PCR (dPCR) and qPCR market is ... 2019. Although the mature markets such as the U.S., Germany, France ... qPCR market the Asia-Pacific region is expected to grow at the ... the digital PCR (dPCR) and qPCR market is driven by factors ...
(Date:3/5/2015)... 05, 2015 A Bakersfield, Calif. state court ... trial awarding the plaintiff Coleen M. Perry a total ... of a TVT-Abbrevo pelvic mesh sling device, manufactured by Ethicon, ... Cartmell , a partner at Wagstaff & Cartmell ... the plaintiff, along with Rich Freese and Tim Goss of ...
(Date:3/5/2015)... New York (PRWEB) March 05, 2015 ... men who allegedly suffered heart attacks, strokes and other ... low testosterone therapies continue to move forward in the ... Northern District of Illinois. According to a Case Management ... forth procedures for the use of master pleadings in ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 ... this March with extra savings on their ... important of health and nutrition, HomeCEUConnection.com is ... using the promo code, NUTRITION2015 . ... Professionals , HomeCEUConnection.com provides high-quality continuing ...
Breaking Medicine News(10 mins):Health News:Nearly 113 Million U.S. Residents Now Reaping Benefits of National Public Health Department Accreditation 2Health News:Nearly 113 Million U.S. Residents Now Reaping Benefits of National Public Health Department Accreditation 3Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 3Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 4Health News:Client Wins $5.7 Million in TVT-Abbrevo Verdict against Johnson & Johnson in California State Court 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 4Health News:HomeCEUConnection.com Offers Nutrition CEUs this March to Celebrate Nutrition Month 2
(Date:3/5/2015)...  Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... chronic pain, today announced the appointment of several ... panel of experts will provide support for planning ... the company pipeline of novel investigational therapies to ... range of areas including opioid receptors, addiction, psychiatry, ...
(Date:3/5/2015)... -- LUNGevity Foundation, the nation,s leading lung cancer ... approval of Bristol Myers Squibb,s new immunotherapy drug ... another critical new treatment option to fight lung ... own immune system to fight cancerous cells. Importantly, ... with squamous cell lung cancer, a population for ...
(Date:3/5/2015)... , Mar. 05, 2015 Research and Markets ... the "Japan Pharma Outlook 2015: Year to Watch ... Initiatives" report to their offering. ... from April -2014 (Annexure 1) is a ... - whether generic or innovator. The most of the ...
Breaking Medicine Technology:Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 2Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 4LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 2LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 3Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 2Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 3
Cached News: